Idecabtagene vicleucel not checked

Celgene · bb2121 · BMS-986395

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
None yet
 
Trials
4 active
10 in total · 6 in the EU
Targets
 

What this is

How it works
A gene therapy: delivers a gene into the patient's cells so they make a protein they lack.-gene: gene therapy substances WHO name stem
Tested for
Multiple Myeloma
Main trialPhase 3
“The purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed Multiple Myeloma (NDMM) who have achieved a suboptimal response post autologous stem cell transplantation (ASCT).”In the company’s words, NCT06045806 on ClinicalTrials.gov
Other names
bb2121 · BMS-986395 · ide-cel · Abecma

Other drugs for Multiple Myeloma

All 133 drugs for Multiple Myeloma

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials10

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 11 Aug 2025 A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
Phase 3Completed 13 Apr 2026 Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
Phase 2Completed 20 Dec 2023 Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma
Phase 2Completed 15 Jan 2026 An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma
Phase 1Completed 22 Jul 2019 Study of bb2121 in Multiple Myeloma
Phase 1Completed 7 Jun 2023 A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)
Phase 1Terminated 25 Apr 2025 Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma
Phase 2/3Authorised not given LONG-TERM FOLLOW-UP PROTOCOL FOR SUBJECTS TREATED WITH GENE-MODIFIED T CELLS
Phase 4Authorised not given Temporal characterization of Extracellular Vesicles during cellular therapy using CAR-T cells and during the occurrence of Immune effector Cell-Associated Neurotoxicity Syndrome : the VESICANS study
Phase 1/2Authorised not given A phase I/II study of CAR-T cells in AutoiMmune disease resistant to B cell Abrogation - CARAMBA
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Idecabtagene vicleucel

Following is part of Solo: you see every change to Idecabtagene vicleucel the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in